Study S001799

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Participants With Atherosclerotic Cardiovascular Disease (ASCVD)

ClinicalTrials.gov record

Registration

Registration: NCT07551492
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 9262
Start: 2026-05-29
Primary completion: 2031-05-24
Lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions: Atherosclerotic Cardiovascular Disease
Interventions: DRUG:HRS9531; DRUG:HRS9531 placebo
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

The time from randomization to the first occurrence of the MACE-3 composite endpoint [approximately up to 61 months of treatment]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.